Hemab Therapeutics launches IPO to sell 11.8 million shares at $16-$18 each

2 articles · Updated · MarketWatch · Apr 27

The Cambridge, Massachusetts-based biotech expects to raise about $180.3 million, or $208.2 million if underwriters exercise their option, with a market cap nearing $700 million.
Proceeds are intended to fund Hemab's operating expenses and capital needs into the second half of 2028, supporting its development of therapies for blood coagulation disorders.
Novo Nordisk Foundation is a major investor in Hemab, which plans to list on the Nasdaq Global Select Market under the symbol COAG.

Is Hemab's $700M valuation the new benchmark for biotech IPOs in 2026?

Will Hemab’s rare disease drug deliver the blockbuster returns IPO investors now expect?

How does Novo's long-term backing shape Hemab's strategy versus VC-funded rivals?

How will this high-stakes IPO impact the future cost of therapy for patients?

Beyond its lead candidate, what does Hemab's pipeline reveal about its long-term vision?

Can a Breakthrough Designation alone guarantee a successful IPO for a clinical-stage company?